ArticleFrontiers in medicine2026
Efficacy and mechanisms of low-frequency TENS for common multimorbidity in older adults: protocol for a pilot randomized controlled trial.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multimorbidity (co-occurrence of ≥2 chronic conditions) in older adults is a global health challenge, often managed with polypharmacy that carries risks of adverse events and drug-drug interactions. As a pilot randomized controlled trial (RCT), this study first aims to assess the feasibility of low-frequency transcutaneous electrical nerve stimulation (Lo-TENS) delivery in older adults with multimorbidity and estimate effect sizes for a subsequent definitive trial. Second, we examine the efficacy of Lo-TENS as an adjunct to routine clinical management for improving blood pressure, glycemic control, and lipid profiles, and explore the underlying autonomic nervous system (ANS) modulation mechanisms through analysis of heart rate variability and key inflammatory/metabolic biomarkers, which are hypothesized to mediate Lo-TENS's beneficial effects on clinical indicators. Methods: A pilot single-center, single-blinded, sham-controlled RCT will enroll 50 older adults (≥60 years) with multimorbidity (≥2 of EH, T2DM, hyperlipidemia). Participants will be randomly allocated (1,1) to receive Lo-TENS (2 Hz, 30 min/day, 5 days/week for 4 weeks) plus routine care or sham Lo-TENS plus routine care. Co-primary outcomes are office systolic blood pressure (SBP), fasting blood glucose (FBG), and low-density lipoprotein cholesterol (LDL-C) at post-intervention. Secondary outcomes include 24-h ambulatory BP, heart rate variability (HRV), inflammatory/metabolic biomarkers, and quality of life. Mechanistic analyses will explore mediation by ANS and inflammatory markers. Follow-up assessments will be conducted 4 weeks post-intervention. Discussion: This trial will provide evidence on the effectiveness of Lo-TENS on clinical outcomes in multimorbidity in older adults, and explore the underlying mechanisms through which Lo-TENS may alleviate the clinical indicators of multimorbidity, specifically by analyzing heart rate variability and key inflammatory and metabolic biomarkers. Trial registration: www.chictr.org.cn, identifier ChiCTR2400093956.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.